Drug Trial Radar · NCT07742280
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Aug 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Bostal Drug Delivery Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the pharmacokinetics (PK), safety and tolerability of Brexpiprazole, administered subcutaneously, in subjects with schizophrenia.
Conditions
- Schizophrenia
Interventions
Brexpiprazole for ER injection, 45 mgDrug
Single-dose, Subcutaneous
Brexpiprazole for ER injection, 100 mgDrug
Single-dose, Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Pre-dose to 190 days post-dose
- ClastTime frame: Pre-dose to 190 days post-dose
- TmaxTime frame: Pre-dose to 190 days post-dose
- AUC0-lastTime frame: Pre-dose to 190 days post-dose
- KelTime frame: Pre-dose to 190 days post-dose
- T1/2Time frame: Pre-dose to 190 days post-dose
- Vd/FTime frame: Pre-dose to 190 days post-dose
- CL/FTime frame: Pre-dose to 190 days post-dose
- MRTTime frame: Pre-dose to 190 days post-dose
- AUC_%Extrap_obsTime frame: Pre-dose to 190 days post-dose
- AEsTime frame: Day 1 to Day 190
- SAEsTime frame: Day 1 to Day 190
- Change from baseline in physical examination findingsTime frame: Day 1 to Day 190
- Blood PressureTime frame: Day 1 to Day 190
- Orthostatic hypotensionTime frame: Day 1 to Day 190
- Columbia-Suicide Severity Rating Scale (C-SSRS) assessmentTime frame: Day 1 to Day 190
- Clinical Laboratory TestsTime frame: Day 1 to Day 190
- 12-lead ECG AssessmentTime frame: Day 1 to Day 190
- Pulse RateTime frame: Day 1 to Day 190
- Respiratory RateTime frame: Day 1 to Day 190
- Body TemperatureTime frame: Day 1 to Day 190
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.